RM Global Partners
RM Global Partners is an investment banking and strategic advisory firm based in New York, founded in 1992. The firm specializes in the life sciences sector, which includes pharmaceuticals, medical devices, biotechnology, healthcare IT, and diagnostics. With a diverse team of experienced professionals, RM Global Partners offers strategic and financial advice to a wide range of clients, from startups to multinational corporations. The firm has a broad international presence across the Americas, Europe, Israel, and Asia, leveraging its extensive network of corporations, investment funds, institutional investors, family offices, and industry experts to facilitate transactions. The firm has a strong track record in mergers and acquisitions, private placements, and other financial services, having completed significant transactions and raised substantial capital for its clients. RM Global Partners is committed to fostering long-term relationships that enhance value for both its clients and investors.
Top Sectors
5 past transactions
ImmPACT Bio
Series B in 2022
ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells specifically designed to target and treat solid tumors. By utilizing advanced technology, the company aims to create chimeric antigen receptor (CAR) T-cell therapies that exhibit tumor specificity, allowing them to induce cytotoxicity only when interacting with tumor cells while sparing healthy tissues. This selective targeting mitigates the safety risks commonly associated with existing CAR-T therapies, providing a promising approach to cancer treatment that enhances efficacy and reduces potential harm to noncancerous cells.
ImmPACT Bio
Series A in 2020
ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells specifically designed to target and treat solid tumors. By utilizing advanced technology, the company aims to create chimeric antigen receptor (CAR) T-cell therapies that exhibit tumor specificity, allowing them to induce cytotoxicity only when interacting with tumor cells while sparing healthy tissues. This selective targeting mitigates the safety risks commonly associated with existing CAR-T therapies, providing a promising approach to cancer treatment that enhances efficacy and reduces potential harm to noncancerous cells.
ProteKt Therapeutics
Venture Round in 2019
ProteKt Therapeutics is a drug development company focused on creating potent and selective oral inhibitors of the kinase PKR to address neurodegenerative and neuroinflammatory diseases. The company has successfully developed a series of novel molecules through innovative computational methods, followed by validation in clinically relevant assays. These inhibitors aim to improve memory consolidation and enhance long-term memory in patients suffering from these conditions. ProteKt Therapeutics has raised $4 million in a pre-A funding round and is a graduate of the FutuRx accelerator, which supports emerging biotechnology ventures.
BiomX
Series B in 2019
BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.
Mitoconix Bio
Series A in 2017
Mitoconix Bio Ltd, founded in 2016 and based in Jerusalem, Israel, is focused on developing innovative therapies aimed at enhancing mitochondrial health to address neurodegenerative diseases. The company seeks to improve mitochondrial functions, which are crucial for energy production, cellular metabolism, and maintaining cellular balance. Mitochondria play a vital role in neuronal health through processes such as fission and fusion, which are essential for their motility and functionality. Disruptions in these processes can lead to decreased energy production, increased oxidative stress, and cell death. Mitoconix's lead drug is a pioneering inhibitor that targets pathological mitochondrial fragmentation and dysfunction, demonstrating efficacy in animal models of Huntington’s and Parkinson’s diseases, as well as beneficial effects in patient-derived cells associated with these and Alzheimer’s disease.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.